Prolight Diagnostics, together with the subsidiary Psyros Diagnostics and technology partners, develops innovative, flexible, patient-centered test systems, Point Of Care Testing (POCT), which is based on patented technology. POC tests are performed outside the traditional hospital laboratory with small mobile instruments in, for example, health centers, nursing homes, emergency rooms and intensive care units, which enables testing close to the patient and with fast test results. This technology will mean that care at an early stage of diagnosis can distinguish the patients who need care quickly from the patients who, for example, do not have a heart attack. The global sales value in the POCT area amounted to USD 34,6 billion in 2021 and is growing strongly.
The company's shares are traded under the short name PRLD on the marketplace NGM Nordic SME.